glp-1 coverage news CMS Extends Medicare's Short-Term Bridge Program for Obesity Drug Paving the way for expanded

This has increased interest in pharmacological treatment options

Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand

Gastrointestinal side effects are a little more common in the oral version than in the injectables

Glucagon-like peptide-1 (GLP-1) mimetics are a class of recently developed diabetes therapy that do not lead to hypoglycemic, but some reports have suggested a relationship between GLP-1 mimetics and ketogenesis

Package Dimensions: 3.5 x 1.8 x 1.8 inches

Coverage of GLP-1 weight-loss drugs is growing among the largest employers (5000+ workers), now at 43%